Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
Definium Therapeutics, Inc. (NASDAQ: DFTX) announced it will report its full-year 2025 financial results and provide business updates on Thursday, February 26, 2026, at 4:30 p.m. EST via a live webcast. The company is a late-stage clinical biopharmaceutical firm focused on developing therapeutics for psychiatric and neurological disorders. A replay of the webcast will be available on their Investor Relations website.
How Mind Medicine (mindmed) Inc. (MNMD) Affects Rotational Strategy Timing
This article from Stock Traders Daily discusses how Mind Medicine (mindmed) Inc. (MNMD) impacts rotational strategy timing. It presents AI-generated trading signals and outlines various strategies like Position Trading, Momentum Breakout, and Risk Hedging, though specific entry/exit points are listed as N/A. The piece emphasizes the platform's AI models for risk management and real-time signal analysis.
Definium Therapeutics Announces New Employee Inducement Grants - February 3, 2026
Definium Therapeutics announced inducement grants to two new non-executive employees, consisting of options to purchase 28,640 common shares. These options, with an effective grant date of February 2, 2026, have an exercise price equal to the closing price on the grant date and will vest over four years. This move aims to attract and retain talent as Definium Therapeutics continues its mission to develop new treatments for psychiatric and neurological disorders.
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics announced inducement grants of options to purchase 28,640 common shares to two new non-executive employees. These options vest over four years, with 25% vesting on the first anniversary and the remainder monthly over the subsequent three years, subject to continued employment. The grants were approved by the Compensation Committee in accordance with NASDAQ rules and are external to the company's equity incentive plans.
Definium Therapeutics Appoints Roger Adsett to Board of Directors
Definium Therapeutics, Inc. has announced the appointment of Roger Adsett to its Board of Directors. Adsett, a seasoned biopharmaceutical leader with over two decades of experience, will bring his commercial, operational, and launch expertise to support Definium's growth, especially as the company anticipates three Phase 3 readouts in 2026. He previously held significant roles at Insmed, Shire, and AstraZeneca, contributing to global commercial strategies and major drug launches.
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics, Inc. announced the issuance of inducement grants to three new non-executive employees, consisting of options to purchase 88,850 common shares. These options, with grant dates of January 12 and January 26, 2025, will vest over four years, with 25% on the first anniversary and the remainder monthly over the following three years, subject to continued employment. The grants were approved by Definium's Compensation Committee and are outside the company's equity incentive plans, in accordance with NASDAQ rules.
DFTX Stock Price and Chart — NASDAQ:DFTX
This article provides a detailed overview of Definium Therapeutics, Inc. (DFTX) stock, including its current price, historical performance, key financial statistics, and upcoming earnings report. It also features analyst ratings, information on ETFs holding DFTX, and answers to frequently asked questions about the company's stock. The stock has shown significant 1-year growth but also considerable volatility.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Rating of "Buy" from Brokerages
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) has received a consensus "Buy" rating from twelve brokerages, with an average one-year target price of $30.33. The company's stock recently traded around $14.96, and key activities include insider stock sales by the CEO and another insider, alongside increased institutional holdings by several major funds. MindMed is a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for mental health and neurological disorders.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Short Interest Update
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) experienced a significant 19.4% increase in short interest, reaching over 15 million shares by December 31st, representing 15.6% of its stock. Despite this, analysts maintain a "Buy" consensus rating with an average price target of $30.33, while the stock currently trades near $14.96. Recent insider sales totaling over $561,000 and a missed quarterly EPS consensus highlight some potential concerns amidst institutional investors increasing their holdings.
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care
Definium Therapeutics has launched "Rerouting Minds," an educational campaign designed to increase understanding of pharmaceutical lysergide (LSD) and its potential role in mental health care. The campaign aims to provide scientific context and highlight the rigorous research exploring LSD's efficacy in addressing severe mental health disorders, given that nearly one in four U.S. adults experiences a mental health disorder with many not receiving treatment. Definium Therapeutics, formerly Mind Medicine (MindMed) Inc., emphasizes applying scientific rigor to psychedelics to develop accessible treatments and reshape psychiatry.
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder - Psychedelic Alpha
MindMed (NASDAQ: MNMD) has initiated its Phase 2b clinical trial for MM-120 (a form of LSD) to treat Generalized Anxiety Disorder (GAD), with the first patient now dosed. This trial is the largest controlled study of LSD ever conducted, building on previous positive data that showed its potential to mitigate anxiety and depression. The study aims to optimize dosage and inform future Phase 3 trials, addressing a significant unmet need for GAD treatments.
New psychedelic legislative efforts in WA; NJ bill passes; MindMed and Cybin rebranding
Washington State is seeing new psychedelic legislative efforts, including bills proposing state-regulated psychedelic services and medical-use-only psilocybin programs. Concurrently, New Jersey passed a bill to fund a $6 million psilocybin research pilot program. Meanwhile, psychedelic companies MindMed and Cybin have announced rebranding efforts, changing their names to Definium and Helus, respectively.
Assessing Mind Medicine (MindMed) (DFTX) Valuation After Rebrand To Deinium Therapeutics And Pipeline Progress
Mind Medicine (MindMed) is rebranding to Deinium Therapeutics and switching its Nasdaq ticker to DFTX on January 15, 2026, which has brought new attention to its psychiatry-focused pipeline. While its Price-to-Book ratio of 11.6x suggests it's overvalued compared to industry averages, a Discounted Cash Flow model indicates a significant undervaluation of 93.5% below an estimated fair value. The article highlights the conflicting valuation methods and encourages investors to consider their own assumptions given the company is still loss-making but has strong share price momentum.
MindMed (MNMN) Options Delisting on January 15th
MindMed (MNMN) will have its options delisted on January 15th, a crucial update for investors given the company's high volatility and speculative nature. The company, a late-stage clinical biopharmaceutical firm, focuses on treatments for brain health disorders with product candidates like MM120 and MM402. Financial health is challenging, marked by no revenue, negative profitability, and ongoing insider selling, despite analyst optimism and upward stock momentum.
MindMed stock rating reiterated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald has reiterated its Overweight rating on MindMed (NASDAQ:MNMD), maintaining a bullish outlook on its DT120 drug candidate for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The firm projects that DT120 could generate $1.7 billion in sales within five years if it achieves similar efficacy in Phase 3 GAD studies. MindMed's stock has shown significant momentum, trading near its 52-week high after a 132.5% return over the past year.
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD)
Mind Medicine (MindMed) has rebranded as Definium Therapeutics, trading under the ticker "DFTX." This move signals a pivot towards late-stage psychiatry drug development, with a specific focus on DT120 for generalized anxiety disorder and major depressive disorder. The company faces significant financial risks, including ongoing losses and the need for successful Phase 3 trial results in 2026 to validate its investment narrative.
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD)
Mind Medicine (MindMed) has rebranded as Definium Therapeutics, now trading on Nasdaq under the ticker "DFTX," to emphasize its focus on next-generation psychiatric and neurological treatments. The company is pivoting towards late-stage psychiatry drug development with its orally disintegrating tablet, DT120, which is currently in three Phase 3 studies for generalized anxiety disorder and major depressive disorder. This rebrand and specific drug focus highlight a high-risk, high-reward investment narrative centered on the success of DT120's forthcoming Phase 3 data in 2026.
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
MindMed has rebranded as Definium Therapeutics, marking a strategic shift to emphasize its focus on developing innovative therapies for psychiatric and neurological disorders. The company, which will trade under the new Nasdaq ticker "DFTX," is advancing a late-stage pipeline with three Phase 3 study readouts for its lead candidate, DT120 ODT, expected in 2026 for generalized anxiety disorder (GAD) and major depressive disorder (MDD). Definium aims to provide long-term remission by addressing the underlying causes of these conditions, with an initial focus on leveraging the clinical potential of psychedelics.
Definium points the way forward as MindMed drops old identity
Mind Medicine has rebranded as Definium Therapeutics, ahead of critical Phase 3 data readouts for its lead psychedelic drug candidate, DT120 ODT, an LSD formulation for generalized anxiety disorder and major depressive disorder. The company aims to leverage existing infrastructure from treatments like Johnson & Johnson’s Spravato for its potential launch. Its Nasdaq ticker has also changed from "MNMD" to "DFTX."
MindMed stock soars 73% since InvestingPro’s undervalued call in May 2024 By Investing.com
MindMed (NASDAQ: MNMD) stock has surged by 73% since InvestingPro identified it as undervalued in May 2024, when it was trading at $8.22. The biotechnology company, focused on psychedelic-inspired medicines for mental health, is now trading at $13.84, exceeding InvestingPro's initial 57% upside projection. This success is attributed to MindMed's advancing clinical pipeline, financial strengthening, and positive regulatory developments in psychedelic therapy.
Mind Medicine stock hits 52-week high at $14.46 By Investing.com
Mind Medicine Inc. (MNMD) reached a new 52-week high of $14.46, reflecting significant investor confidence and a remarkable 89.97% 1-year return. Despite missing Q3 2025 earnings forecasts, the company is attracting attention due to strategic advancements, positive analyst ratings, and strong liquidity, particularly in the psychedelic medicine sector as it advances clinical trials.
Mind Medicine stock hits 52-week high at $14.46 By Investing.com
Mind Medicine Inc. (MNMD) reached a new 52-week high of $14.46, reflecting significant investor confidence and a remarkable 89.97% 1-year return. Despite a recent earnings per share miss, the company's strong liquidity and progress in clinical trials in the psychedelic medicine sector contribute to a cautiously optimistic market outlook. Analyst targets range from $16 to $61, with InvestingPro indicating potential undervaluation, further fueled by positive regulatory developments.
Mind Medicine stock hits 52-week high at $14.46
Mind Medicine Inc. (MNMD) saw its stock price reach a 52-week high of $14.46, reflecting significant investor confidence and an 89.97% one-year return. Despite a recent earnings miss, the company's advancements in psychedelic medicine, favorable analyst ratings, and the progression of a psilocybin therapy bill in New Jersey have contributed to a positive market outlook. InvestingPro indicates the stock may still be undervalued, with analyst price targets up to $61.
Mind Medicine (MindMed) (NASDAQ:MNMD) Sets New 52-Week High - Still a Buy?
Mind Medicine (MindMed) (NASDAQ:MNMD) recently reached a new 52-week high of $14.81, though it last traded at $13.61. Despite a consensus "Buy" rating and an average price target of $30.33 from analysts, the company remains unprofitable with a negative EPS forecast for the current fiscal year. Recent insider sales also indicate potential risks, prompting investors to consider various factors beyond the stock's recent performance.
MindMed stock added to Needham’s Conviction List, analyst reiterates Hold
Needham has named MindMed (NASDAQ:MNMD) as its Top Pick for 2026 and added it to their Conviction List, maintaining a Hold rating and a $28.00 price target. The positive outlook is based on a catalyst-rich 2026 with pivotal readouts for generalized anxiety disorder (GAD) and major depressive disorder (MDD), and the potential for MM120 to generate $2.5 billion in U.S. sales by 2035. The stock has seen a 90% return in the past six months and its balance sheet provides a runway into 2028.
The Technical Signals Behind (MNMD) That Institutions Follow
This article provides a technical analysis of Mind Medicine (mindmed) Inc. (NASDAQ: MNMD), highlighting institutional trading strategies and AI-generated signals. It identifies a near-term neutral sentiment amidst mid and long-term strength, along with specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies. The analysis also covers multi-timeframe signal strengths, support, and resistance levels.
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3.8% on Insider Selling
Mind Medicine (MindMed) (NASDAQ:MNMD) experienced a 3.8% stock decline following insider selling on December 26th by CEO Robert Barrow, Mark Sullivan, and Daniel Karlin. Despite this, analyst sentiment remains largely positive with a consensus "Buy" rating and an average price target of $30.33, fueled by a near-term clinical catalyst as MM-120 moves into Phase III with pivotal readouts expected in 2026. The company, which has a $1.28 billion market cap and solid liquidity, is focused on developing psychedelic-inspired therapies for mental health and neurological disorders.
Mind Medicine (MindMed) (NASDAQ:MNMD) Insider Mark Sullivan Sells 11,276 Shares
Mind Medicine (MindMed) insider Mark Sullivan sold 11,276 shares of the company's stock on December 26th at an average price of $13.15, totaling $148,279.40. This transaction reduced his position by 3.84% to 282,576 shares. Following the sale, MNMD stock traded up 3.1% to $13.46, though the company recently missed quarterly EPS estimates and analysts forecast a negative full-year EPS.
What's Driving JonesTrading's Bullish View on Mind Medicine (MindMed) Inc. (MNMD)
JonesTrading has initiated coverage on Mind Medicine (MindMed) Inc. (MNMD) with a ‘Buy’ rating and a $61 price target, anticipating strong clinical data from its lead asset MM120 for generalized anxiety disorder and major depressive disorder. Analyst Patrick Trucchio also reaffirmed a ‘Buy’ rating with a $55 price target. The company, specializing in novel treatments for brain health using psychedelic agents, is a consensus buy among thirteen analysts, with a median price target of $24.50.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of "Buy" from Analysts
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) has received an average "Buy" rating from twelve analysts, with an average 12-month price target of $30.33. The company, which focuses on psychedelic-inspired therapies, recently missed quarterly EPS estimates but institutional investors are increasing their stakes. Key programs include MM-120 for anxiety, MM-310 for addiction, and MM-402 for mood/stress.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Rating of "Buy" from Analysts
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) has received a consensus "Buy" rating from twelve analysts, with an average 12-month price target of $30.33. The clinical-stage biopharma company, which develops psychedelic-inspired therapies, reported quarterly EPS of ($0.78) against an expected ($0.52). Institutional investors own approximately 27.9% of the company's stock, with some increasing their stakes recently.
Is MindMed (MNMD) Turning Psychedelic Policy Tailwinds Into a Durable Neuropsychiatry Advantage?
Jones Trading initiated coverage on Mind Medicine (MindMed) with a positive outlook on its MM120 program for generalized anxiety disorder and major depressive disorder, noting the company's strong position in psychedelic drug development. While emerging New Jersey legislation on psilocybin access is helpful, MindMed faces challenges given its zero revenue, rising net losses, and dependence on MM120. Investors have widely divergent fair value estimates for the company, highlighting the speculative nature of the investment.
Is MindMed (MNMD) Turning Psychedelic Policy Tailwinds Into a Durable Neuropsychiatry Advantage?
Jones Trading initiated research on Mind Medicine (MindMed) with an optimistic view on its MM120 program for generalized anxiety disorder and major depressive disorder, seeing the company positioned well in psychedelic drug development. The firm also noted emerging New Jersey legislation supporting regulated therapeutic psilocybin access, suggesting favorable policy changes could impact MindMed positively. However, investors should be aware of the company's reliance on MM120, its current zero revenue, rising net losses, and relatively expensive balance sheet despite the recent equity raise.
Jones Trading Initiates Coverage of Mind Medicine (MNMD) with Buy Recommendation
Jones Trading has initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy recommendation, according to a report from Fintel on December 23, 2025. Analysts project an 86.65% upside with an average one-year price target of $26.15/share. The article also details institutional ownership changes, highlighting a decrease in overall shares owned by institutions but some individual funds increasing their allocations.
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap Up - Time to Buy?
Mind Medicine (MindMed) (NASDAQ:MNMD) experienced a pre-market stock price gap up, opening at $13.65 after closing at $13.30 and trading near $13.95. The company's stock is trading above its 50-day and 200-day moving averages, and analysts generally have a bullish sentiment with a consensus target price of $30.33, despite the company remaining unprofitable. Insider selling was noted, reducing overall insider ownership in the company.
Jones Trading initiates coverage on MindMed stock with Buy rating
Jones Trading initiated coverage on Mind Medicine (NASDAQ:MNMD) with a Buy rating and a $61.00 price target, citing the company's potential in developing psychedelic agents for neuropsychiatry. Despite regulatory risks associated with MM120 (LSD), strong Phase III data is expected to lead to approval, with the market potentially underestimating the opportunity. MindMed's stock has performed strongly in 2025, rising approximately 91% year-to-date.
Jones Trading Begins Coverage on Mind Medicine (MindMed) (NASDAQ:MNMD)
Jones Trading has initiated coverage on Mind Medicine (MindMed) (NASDAQ:MNMD) with a "buy" rating and a price target of $61.00, suggesting a significant potential upside of 358.65%. The stock currently has an average analyst rating of "Buy" and a consensus target price of $30.33, despite analysts forecasting negative earnings per share for the fiscal year. While institutional ownership is substantial, insiders have recently sold shares.
Assessing Mind Medicine (MNMD)’s Valuation After a Strong Recent Share Price Rally
Mind Medicine (MindMed) (MNMD) has seen a significant share price rally, up roughly 66% year-to-date, indicating increasing investor interest in its brain health pipeline. While its Price to Book ratio of 9.5 times suggests an overvalued status compared to peers, a Discounted Cash Flow (DCF) model indicates the stock might be trading below its fair value at $21.49, implying potential undervaluation. Investors are cautioned that clinical setbacks or ongoing losses could impact current optimism despite the strong momentum.
Assessing Mind Medicine (MNMD)’s Valuation After a Strong Recent Share Price Rally
Mind Medicine (MindMed) (MNMD) has seen significant share price appreciation year-to-date and over the past three months, indicating growing investor interest in its brain health pipeline. Despite this rally, the stock still trades at a steep discount to analyst targets according to some valuation models, while other metrics suggest overvaluation. The article explores different valuation perspectives, including Price to Book and Discounted Cash Flow models, to assess whether MNMD is an underappreciated growth story or if its future potential is already priced in.
Brain health biotech anticipates 3 Phase 3 readouts after JP Morgan talk
Mind Medicine (MindMed) Inc. announced that its CEO, Rob Barrow, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is a late-stage clinical biopharmaceutical company focusing on brain health disorders and anticipates three Phase 3 topline readouts in the coming year. These readouts could lead to potential FDA submissions for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD) treatments.
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
Mind Medicine (MindMed) Inc. announced that CEO Rob Barrow will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. This presentation offers MindMed an opportunity to engage with investors ahead of a defining year, with three anticipated Phase 3 topline readouts and potential FDA submissions for GAD and MDD treatments. A live audio webcast of the presentation will be available for interested parties.
MindMed Announces New Employee Inducement Grant
Mind Medicine (MindMed) Inc. announced the issuance of inducement grants to two new non-executive employees. These grants consist of options to purchase an aggregate of 31,500 common shares, with an effective grant date of December 15, 2025. The options have an exercise price equal to the closing price on the grant date and will vest over four years, subject to continued employment.
Stempoint Capital LP Makes New $590,000 Investment in Mind Medicine (MindMed) Inc. $MNMD
Stempoint Capital LP recently initiated a new investment in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), purchasing 90,852 shares valued at approximately $590,000. Despite recent insider selling, institutional investors have been increasing their stakes, and analysts maintain a consensus "Buy" rating with an average price target of $26.50 for the clinical-stage biopharmaceutical company. MindMed is focused on developing therapies for brain health disorders, with lead candidates in trials for generalized anxiety disorder and autism spectrum disorder.
Diadema Partners LP Makes New Investment in Mind Medicine (MindMed) Inc. $MNMD
Diadema Partners LP has announced a new investment in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), acquiring 158,536 shares valued at approximately $1.03 million. This new stake represents about 0.21% ownership and positions Diadema among other institutional investors who now collectively hold about 27.91% of MindMed. Despite recent insider selling and a Q3 EPS loss, analysts maintain a "Buy" consensus rating with a target price of $26.50.
Marshall Wace LLP Has $22.20 Million Holdings in Mind Medicine (MindMed) Inc. $MNMD
Marshall Wace LLP significantly increased its stake in Mind Medicine (MindMed) Inc. by 31.9%, now holding 3,421,224 shares valued at $22.20 million. Despite this institutional accumulation, insiders like Daniel Karlin and Mark Sullivan have recently sold shares, reducing insider ownership to 2.26%. Analysts maintain a "Buy" rating with a consensus price target of $26.50, even though the company recently missed quarterly EPS estimates and trades near $13.
MindMed Announces New Employee Inducement Grants
Mind Medicine (MindMed) Inc. announced the issuance of inducement grants to four new non-executive employees. These grants consist of options to purchase an aggregate of 182,100 common shares, with vesting over a four-year period. The grants were approved by MindMed's Compensation Committee and are outside its equity incentive plans, aligning with NASDAQ rules.
Mind Medicine (MNMD) Reports Wider Loss and Major Equity Raise, How Will Capital Shape Its R&D Ambitions?
Mind Medicine (MindMed) reported a significant increase in its net loss for the third quarter, reaching US$67.27 million, while simultaneously completing a US$225 million equity offering to support its R&D and potential acquisitions. This capital raise is expected to fund future growth and operational needs, with a heightened focus on advancing its clinical development, particularly the Phase 3 MM120 studies for Generalized Anxiety Disorder. Despite addressing short-term cash needs, the company still faces potential dilution for shareholders and increased pressure to deliver meaningful clinical trial data.
Mind Medicine stock soars after New Jersey advances psilocybin bill
Mind Medicine Inc (NASDAQ:MNMD) stock surged 9.6% after New Jersey lawmakers advanced a bill to provide regulated therapeutic access to psilocybin for adults with qualifying health conditions. The legislation establishes a framework for licensed psilocybin therapy and includes provisions for a social equity program. This move is seen as significant progress for psychedelic therapy, potentially expanding the market for companies like Mind Medicine, a biopharmaceutical company focused on brain health disorders.
Will Larger-Than-Expected Losses Alter Mind Medicine (MNMD)'s Investment Narrative?
Mind Medicine (MindMed) reported significantly larger net losses in Q3 2025, reaching US$67.27 million, primarily due to increased research and development. This amplifies concerns about the company's "burn rate" and potential dilution, despite a recent equity offering. The article explores how these greater-than-anticipated losses impact MindMed's investment narrative, intensifying focus on clinical trial success for its psychedelic-based mental health therapies before capital is depleted.
Mind Medicine Inc. Announces Proposed Public Offering
Mind Medicine (MindMed) Inc. announced its intent to offer common shares and pre-funded warrants in an underwritten public offering, with an option for underwriters to purchase additional shares. The company plans to use the net proceeds to fund research and development of its product candidates, for working capital, and general corporate purposes, potentially including acquisitions. Jefferies LLC, Leerink Partners, and Evercore ISI are acting as joint bookrunning managers for the offering, which is subject to market conditions.
